PHOJY yields 9.05% · JNJ yields 2.13%● Live data
📍 PHOJY pulled ahead of the other in Year 1
Combined, PHOJY + JNJ cover 0 of 12 months — good coverage
Which stock is actually better after tax? Adjust your rate to find out.
What's the optimal mix of PHOJY + JNJ for your $10,000?
Public Joint-Stock Company PhosAgro, together with its subsidiaries, engages in the production and distribution of apatite concentrate and mineral fertilizers in Russia and internationally. It operates in two segments, Phosphate-Based Products and Nitrogen-Based Products. The Phosphate-Based Products segment produces and distributes ammophos, diammoniumphosphate, sodium tripolyphosphate, and other phosphate based and complex fertilizers; and apatite concentrate extracted from the apatite-nepheline ore. The Nitrogen-Based Products segment is involved in the production and distribution of ammonia, ammonium nitrate, and urea. It also offers feed phosphates; phosphate rock; and industrial products, such as syenite alkali aluminum concentrate, titanomagnetite concentrate, nepheline concentrate, aegirine concentrate, oleum, sulphuric acid, sodiumsilicofluoride, aluminum fluoride, nitric acid, and ammonia solution. Public Joint-Stock Company PhosAgro was incorporated in 2001 and is headquartered in Moscow, the Russian Federation.
Full PHOJY Calculator →Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the healthcare field worldwide, but strategically separated its Consumer Health business into Kenvue Inc. in 2023 to focus on its higher-growth, innovation-driven segments; the former Consumer Health brands (including TYLENOL, LISTERINE, and BAND-AID) are now owned by Kenvue. The company's core focus is now split between its Innovative Medicine (formerly Pharmaceutical) segment, which offers prescription products for complex diseases such as rheumatoid arthritis, various cancers, HIV/AIDS, and neurodegenerative disorders; and its MedTech (Medical Devices) segment, which provides advanced technology solutions including electrophysiology products, neurovascular care products, orthopaedics (hips, knees, spine), advanced surgery solutions, and disposable contact lenses under the ACUVUE brand. Company's two remaining segments primarily serve hospitals, healthcare professionals, wholesalers, and retailers, continuing its mission of advancing human health since its founding in 1886 and its current basing in New Brunswick, New Jersey.
Full JNJ Calculator →Save your analysis + weekly dividend insights. Free forever.
⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.